Cell & Gene Therapy From DNA to Therapy: Exploring Plasmid Applications, LVV Manufacturing, and Regulatory Insights 04-22-2025 / Luffy Chen, Head of Plasmid PD and Production Dept., ProBio Join us on April 22ⁿᵈ for an exclusive webinar on Cell and Gene Therapy (CGT) development! Gain expert knowledge on optimizing plasmid and LVV production timelines, ensuring regulatory compliance, and navigating IND and BLA applications... Learn More
Cell & Gene Therapy Strategies and Solutions for mRNA Therapeutics and Personalized Medicines 05-23-2024 / Dr. Xiao Pan, Director of Platform R&D Dept. Learn More
Cell & Gene Therapy Unlocking Affordability: Cell Therapy Development Strategies to Expand Patient Access 03-28-2024 / Dr. Li Chen, Sr. Director, Biologics Discovery Dept. ProBio VHH is a novel modality in antibody based therapy. Its naturally generated single-domain structure makes it an ideal building block in cell therapy. Learn More
Cell & Gene Therapy mRNA One-stop Solution: Plasmid, Linearized DNA, IVT-mRNA, mRNA-LNP and QC sharing 09-05-2023 / Dr. Xiao Pan, Sr. Director, Platform R&D Dept. The production of mRNA therapeutics and vaccines is a complex process that begins with pDNA manufacturing and ends with fill and finish by using different delivery technologies. Learn More
Cell & Gene Therapy Integrated one-stop solution for mRNA CMC 03-28-2023 / Dr. Xiao Pan, Director of Platform R&D Dept., ProBio The production of mRNA therapeutics and vaccines is a complex process that begins with pDNA manufacturing and ends with fill and finish by using different delivery technologies. Currently, there are some mRNA candidates in late-stage trials or commercial Learn More
Cell & Gene Therapy Addressing analytical control challenges for different plasmid DNA products 11-30-2022 / Lauren Lu, Senior Director of QC Dept Addressing analytical control challenges for different plasmid DNA products Learn More
Cell & Gene Therapy Development and manufacturing Strategy for DNA Base Vaccine-Drug Candidates 11-01-2022 / Mark Wei Since the outbreaks of COVID-19, DNA vaccines are promising in the SARS-CoV-2 vaccine race although they have a new platform technology that was not previously available on the market for human use. Learn More
Cell & Gene Therapy Scalable AAV Manufacturing Strategies 07-14-2022 / Dr. Xiao Pan Since the approval of the product Luxtura® using AAV as a vector in 2017, more and more clinical trials have been carried out rapidly, and various early clinical trial projects for rare diseases and a wide range of indications .. Learn More